Similar articles

• Can treatment costs be tamed?

  Malakoff D. Malakoff D. Science. 2011 Mar 25;331(6024):1545-7. doi: 10.1126/science.331.6024.1545. Science. 2011. PMID: 21436438 No abstract available.
• Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.

  Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, Tannock IF, Ocaña A. Amir E, et al. J Clin Oncol. 2011 Jun 20;29(18):2543-9. doi: 10.1200/JCO.2011.35.2393. Epub 2011 May 23. J Clin Oncol. 2011. PMID: 21606435
• Many new cancer drugs in the United Kingdom are facing negative NICE rulings.

  Low E; Myeloma UK. Low E, et al. J Clin Oncol. 2007 Jun 20;25(18):2635-6; author reply 2637-8. doi: 10.1200/JCO.2007.11.4272. J Clin Oncol. 2007. PMID: 17577049 No abstract available.
• [Utilization of antineoplastic agents in Sweden and Europe].

  Wilking N, Jönsson B, Björn W. Wilking N, et al. Lakartidningen. 2010 Apr 21-27;107(16):1075-80. Lakartidningen. 2010. PMID: 20476705 Review. Swedish. No abstract available.
• European perspective on the costs and cost-effectiveness of cancer therapies.

  Drummond MF, Mason AR. Drummond MF, et al. J Clin Oncol. 2007 Jan 10;25(2):191-5. doi: 10.1200/JCO.2006.07.8956. J Clin Oncol. 2007. PMID: 17210939 Review.